Table 2.

Clinical and disease characteristics and B cell repertoire features in patient groups

	SjS (n=26)	Disease controls (n=10)	Healthy controls (n=24)
Female, %	73	70	46
Age in years, mean±SD	54.4±15.3	57±11.8	56.6±14.0
Diagnosis disease controls
SLE, n	–	5	–
SCLE, n	–	3	–
Other, n	–	2	–
Individuals tested for virology, n	24	6	21
CMV-IgG positive, %	42	50	38
VCA-IgG positive, %	92	100	86
EBNA-IgG positive, %	79	67	76
Anti-SSB, n	22	8	–
Anti-SSA, n	26	9	–
RF, n	16	2	–
RF titres in IU/mL, median (IQR)	100 (41.3–207.5)	101 (11–191)	–
SLE antibodies, n	5	4	–
Anti-CCP, n	2	1	–
Individuals tested for serum IgG, n	23	3	–
IgG positive, %	60.9	66.7	–
IgG titres in IU/mL, mean±SD	20.9±4.8	19±7.8	–
Serum cryoglobulins, n	3	1	–
Serum M protein, n	1	0	–
Leucopenia, n	9	2	–
Neutropenia, n	3	1	–
Lymphopenia, n	7	4	–
ESSDAI, median (IQR)	2 (1–2.3)	1 (0–2)	–
Maximal past ESSDAI, median (IQR)	3 (2–5.3)	1.5 (0.3–8)	–
ESR in mm/hour, median (IQR)	20 (7.5–28.5)	8 (2–43)
Concomitant Raynaud, n	15	5	–
Concomitant arthritis, n	4	3	–
Organ involvement, n	5	3	–
WB HES, median (IQR)	2.5 (0.8–6.5)	3.5 (0–7.8)	0.5 (0–4.8)
Percentage of clones with SHM >0 in WB, median (IQR)	60.5 (50.8–75.6)	69.2 (57.6–81.3)	60.1 (52.7–65)
Percentage of clones with N-glycosylation sites >0 in WB, median (IQR)	6 (5–7.6)	7.8 (5.7–9.5)	5.6 (5.2–6.5)
CDR3 length in WB, mean±SD	24±0.4	23.8±0.4	24.3±0.1

CCP, cyclic citrullinated peptides; CDR3, complementarity determining region 3; CMV, cytomegalovirus; EBNA, EBV nuclear antigen; ESR, erythrocyte sedimentation rate; ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; HES, highly expressed sequences; Ig, immunoglobulin; RF, rheumatoid factor; SCLE, subacute lupus erythematosus; SHM, somatic hypermutation; SjS, Sjögren’s syndrome; SLE, systemic lupus erythematosus; VCA, virus capsid antigen; WB, whole blood.